These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 21270910

  • 1. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
    Hernández D, Martínez D, Gutiérrez E, López V, Gutiérrez C, García P, Cobelo C, Cabello M, Burgos D, Sola E, González-Molina M.
    Nefrologia; 2011; 31(1):27-34. PubMed ID: 21270910
    [Abstract] [Full Text] [Related]

  • 2. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
    Helal I, Chan L.
    Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
    [Abstract] [Full Text] [Related]

  • 3. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [Abstract] [Full Text] [Related]

  • 4. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F, Andrés A, Oppenheimer F.
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [Abstract] [Full Text] [Related]

  • 5. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T, Argudo A, Peña-Cala MC.
    Transplant Proc; 2011 Jan; 43(6):2216-9. PubMed ID: 21839237
    [Abstract] [Full Text] [Related]

  • 6. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
    Zeier M, Van Der Giet M.
    Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
    [Abstract] [Full Text] [Related]

  • 7. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L, Kamar N.
    J Nephrol; 2010 Jan; 23(2):133-42. PubMed ID: 20155724
    [Abstract] [Full Text] [Related]

  • 8. Everolimus: efficacy and safety in cardiac transplantation.
    Schaffer SA, Ross HJ.
    Expert Opin Drug Saf; 2010 Sep; 9(5):843-54. PubMed ID: 20701555
    [Abstract] [Full Text] [Related]

  • 9. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.
    Nashan B.
    Clin Transplant; 2013 Sep; 27 Suppl 25():16-29. PubMed ID: 23909498
    [Abstract] [Full Text] [Related]

  • 10. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 11. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

  • 12. Conversion to everolimus in liver transplant patients with renal dysfunction.
    Pérez T, Segovia R, Castro L, Roblero JP, Estela R.
    Transplant Proc; 2011 Jul; 43(6):2307-10. PubMed ID: 21839260
    [Abstract] [Full Text] [Related]

  • 13. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
    Mártinez JM, Pulido LB, Bellido CB, Usero DD, Aguilar LT, Moreno JL, Artacho GS, Díez-Canedo JS, Gómez LM, Bravo MA.
    Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
    [Abstract] [Full Text] [Related]

  • 14. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin.
    Paoletti E, Cannella G.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S41-3. PubMed ID: 21095451
    [Abstract] [Full Text] [Related]

  • 15. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B, Karakayali H, Colak T, Sevmis S, Pehlivan S, Demirhan B, Haberal M.
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [Abstract] [Full Text] [Related]

  • 16. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S, Baroletti SA.
    Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
    [Abstract] [Full Text] [Related]

  • 17. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?
    Gonzalez-Vilchez F, Vazquez de Prada JA, Paniagua MJ, Gomez-Bueno M, Arizon JM, Almenar L, Roig E, Delgado J, Lambert JL, Perez-Villa F, Sanz-Julve ML, Crespo-Leiro M, Segovia J, Lopez-Granados A, Martinez-Dolz L, Mirabet S, Escribano P, Diaz-Molina B, Farrero M, Blasco T.
    Int J Cardiol; 2014 Jan 15; 171(1):15-23. PubMed ID: 24309084
    [Abstract] [Full Text] [Related]

  • 18. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 19. A drug safety evaluation of everolimus in kidney transplantation.
    Holdaas H, Midtvedt K, Åsberg A.
    Expert Opin Drug Saf; 2012 Nov 27; 11(6):1013-22. PubMed ID: 22954349
    [Abstract] [Full Text] [Related]

  • 20. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct 27; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.